Home | About PM | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Pharmacognosy Magazine
Search Article 
  
Advanced search 
 
ORIGINAL ARTICLE
Year : 2013  |  Volume : 9  |  Issue : 36  |  Page : 350-356

Clinical Evaluation of Commiphora Mukul, a Botanical resin, in the Management of Hemorrhoids: A randomized controlled trial


1 Department of Traditional Iranian Medicine, Faculty of Medicine, Shahed University, Tehran, Iran
2 Department of Physiology, Faculty of Medicine, Research Center for Clinical Trial on Traditional Iranian Medicine (RCCT-TIM), Shahed University, Mashhad, Iran
3 Department of Gastroenterology and Hepatology, Ghaem Hospital, Mashhad, Iran
4 Department of Internal Medicine, Imam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
5 Department of Social Medicine, Faculty of Medicine, Shahed University, Tehran, Iran
6 Department of Pharmacognosy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
7 Department of Biostatistics, Zanjan University of Medical Sciences, Zanjan, Iran

Correspondence Address:
Mohammad Reza Vaez Mahdavi
Faculty of Medicine, No. 29, Abdollah zadeh St., Keshavarz Ave., Tehran
Iran
Login to access the Email id

Source of Support: This work was supported by a grant from Research Council of Shahed University (Tehran)., Conflict of Interest: None


DOI: 10.4103/0973-1296.117832

Rights and Permissions

Background : Hemorrhoids complaint is one of the most common problems in most society, especially in Asian countries. Current drug treatment protocols cannot cure the disease, and they are palliative. According to Persian traditional medicine, Commiphora Mukul (CM) resin is a medication choice. Aim : This randomized study was undertaken to evaluate the efficacy and safety of crude CM resin compared to a combination of lactolose and anti-hemorrhoid (LandA) in patients with uncomplicated hemorrhoids grade 1 and 2. Materials and Methods : This trial was carried out on 99 patients with hemorrhoids, in Ghaem and Imam Reaza Hospitals of the Mashhad University of Medical Sciences, Iran. They randomly received CM 3 g/d for 4 weeks (as study group) or LandA (Lactolose syrup in laxative dose for 1 month and anti-hemorrhoid suppository daily for 10 days) as control group. Subjective and objectives variables including painful defecation, flatulence, constipation, gastro-esophageal reflux (GER), dyspepsia, proctorrhagia, anal protrusion, and colonoscopic grading were assessed before, immediately after, and 4 weeks after the treatment period. An intent-to-treat analysis was used. Safety was assessed with evaluation of clinical adverse effects by common toxicity criteria version 4.0. Forty-nine patients were assigned randomly to receive LandA and 50 to receive CM. After 4 weeks, flatulence, dyspepsia, GER, and colonoscopic grading scores significantly decreased in study group, whereas in control group constipation, painful defecation, and proctorrhagia showed better but not significant improvement. After 4-weak follow-up, the rate of constipation, and proctorrhagia also showed significantly improvement in study group. Constipation and proctorrhagia in control group recurred significantly in 4-week follow-up than after the treatment, whereas this recurrence in test group was not seen. Conclusion : CM was more effective than LandA in 4-week treatment of patients with uncomplicated hemorrhoids grade 1 and 2.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1958    
    Printed40    
    Emailed1    
    PDF Downloaded22    
    Comments [Add]    
    Cited by others 3    

Recommend this journal